Prevention of cardiac hypertrophy in mice by calcineurin inhibition

Science

Volumn 281, Issue 5383, 1998, Pages 1690-1693

  Sussman, Mark A ^a   Lim, Hae W ^a   Gude, Natalie ^a   Taigen, Tyler ^a   Olson, Eric N ^b   Robbins, Jeffrey ^a   Colbert, Melissa C ^a   Gualberto, Antonio ^c   Wieczorek, David F ^d   Molkentin, Jeffery D ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTININ; CALCINEURIN; CYCLOSPORIN; MYOSIN LIGHT CHAIN; TACROLIMUS; TROPOMODULIN; TROPOMYOSIN;

ANIMAL MODEL; ARTICLE; DRUG EFFECT; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HYPERTROPHIC CARDIOMYOPATHY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CALCINEURIN; CALCIUM; CARDIAC MYOSINS; CARDIOMEGALY; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; CARRIER PROTEINS; CYCLOSPORINE; FEMALE; MICE; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; MODELS, CARDIOVASCULAR; MYOCARDIUM; MYOSIN LIGHT CHAINS; RATS; SIGNAL TRANSDUCTION; TACROLIMUS; TROPOMODULIN; TROPOMYOSIN;

EID: 0032508640     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.281.5383.1690     Document Type: Article

References (37)

1. B. J. Maron, J. M. Gardin, J. M. Flack, S. S. Gidding, D. Bild, Circulation 92, 785 (1995); W. T. Abraham and M. R. Bristow, ibid. 96, 2755 (1997).
2. B. J. Maron, J. M. Gardin, J. M. Flack, S. S. Gidding, D. Bild, Circulation 92, 785 (1995); W. T. Abraham and M. R. Bristow, ibid. 96, 2755 (1997).
3. T. M. Olson, V. V. Michels, S. N. Thibodeau, Y.-S. Tai, M. T. Keating, Science 280, 750 (1998); K. L. Vikstrom and L. A. Leinwand, Curr. Opin. Cell Biol. 8, 97 (1996); H. Watkins, J. G. Seidman, C. E. Seidman, Hum. Mol. Genet. 4, 1721 (1995); B. J. Maron, Lancet 350, 127 (1997).
4. T. M. Olson, V. V. Michels, S. N. Thibodeau, Y.-S. Tai, M. T. Keating, Science 280, 750 (1998); K. L. Vikstrom and L. A. Leinwand, Curr. Opin. Cell Biol. 8, 97 (1996); H. Watkins, J. G. Seidman, C. E. Seidman, Hum. Mol. Genet. 4, 1721 (1995); B. J. Maron, Lancet 350, 127 (1997).
5. T. M. Olson, V. V. Michels, S. N. Thibodeau, Y.-S. Tai, M. T. Keating, Science 280, 750 (1998); K. L. Vikstrom and L. A. Leinwand, Curr. Opin. Cell Biol. 8, 97 (1996); H. Watkins, J. G. Seidman, C. E. Seidman, Hum. Mol. Genet. 4, 1721 (1995); B. J. Maron, Lancet 350, 127 (1997).
6. T. M. Olson, V. V. Michels, S. N. Thibodeau, Y.-S. Tai, M. T. Keating, Science 280, 750 (1998); K. L. Vikstrom and L. A. Leinwand, Curr. Opin. Cell Biol. 8, 97 (1996); H. Watkins, J. G. Seidman, C. E. Seidman, Hum. Mol. Genet. 4, 1721 (1995); B. J. Maron, Lancet 350, 127 (1997).
7. K. A. Palmiter and R. J. Solaro, Basic Res. Cardiol. 92, 63 (1997).
8. J. D. Molkentin et al., Cell 93, 215 (1998).
9. R. E. Dolmetsch, R. S. Lewis, C. C. Goodnow, J. I. Healy, Nature 386, 855 (1997); P. De Koninck and H. Schulman, Science 279, 227 (1998).
10. R. E. Dolmetsch, R. S. Lewis, C. C. Goodnow, J. I. Healy, Nature 386, 855 (1997); P. De Koninck and H. Schulman, Science 279, 227 (1998).
11. M. A. Sussman et al., Circ. Res. 82, 94 (1998); M. A. Sussman et al., J. Clin. Invest. 101, 51 (1998).
12. M. A. Sussman et al., Circ. Res. 82, 94 (1998); M. A. Sussman et al., J. Clin. Invest. 101, 51 (1998).
13. TOT mice develop signs of cardiomyopathy by 11 to 12 days after birth. CsA (15 mg/kg of body weight, twice a day) or FK506 (3 mg/kg twice a day) treatment was begun 9 days after birth and continued until day 24. Injections were administered subcutaneously. By day 24, vehicle-treated TOT mice showed a prominent dilated heart phenotype, whereas CsA-and FK506-treated TOT mice did not develop a pathologic phenotype. Nontransgenic mice were treated with CsA over this same period to control for effects on normal developmental cardiac hypertrophy. At least five genetically identical mice were tested within each group. For morphometric measurements, see Science Online (www.sciencemag. org).
14. Cryosections of hearts from TOT mice and nontransgenic mice were prepared for α-actinin and tropo-modulin immunohistochemistry (6). The sections were generated from hearts subjected to the treatment regimens described in (7).
15. H. W. Lim and J. D. Molkentin, data not shown.
16. G. Wiederrecht, E. Lam, S. Hung, M. Martin, N. Sigal, Ann. Acad. Sci. 696, 9 (1993); N. A. Clipstone, D. F. Fiorentirto, G. R. Crabtree, J. Biol. Chem. 269, 26431 (1994); H. Husi, M. A. Luyten. M. G. Zurini, ibid., p. 14199.
17. G. Wiederrecht, E. Lam, S. Hung, M. Martin, N. Sigal, Ann. Acad. Sci. 696, 9 (1993); N. A. Clipstone, D. F. Fiorentirto, G. R. Crabtree, J. Biol. Chem. 269, 26431 (1994); H. Husi, M. A. Luyten. M. G. Zurini, ibid., p. 14199.
18. G. Wiederrecht, E. Lam, S. Hung, M. Martin, N. Sigal, Ann. Acad. Sci. 696, 9 (1993); N. A. Clipstone, D. F. Fiorentirto, G. R. Crabtree, J. Biol. Chem. 269, 26431 (1994); H. Husi, M. A. Luyten. M. G. Zurini, ibid., p. 14199.
19. 32P]adenosine triphosphate-labeled phosphopeptide in the presence or absence of a specific calcineurin autoinhibitory peptide. The conditions of the assay were as described [A. Gualberto et al., J. Biol. Chem. 273, 7088 (1998)].
20. M. C. Schaub, M. A. Hefti, B. A. Harder, H. M. Eppenberger, J. Mol. Med. 75, 901 (1997).
21. J. G. Fewell et al., unpublished data.
22. The MLC2v transgenic mice gradually present with a hypertrophic phenotype by 8 weeks of age. These mice were split into two groups and treated with vehicle or CsA (15 mg/kg twice a day) beginning at 2 weeks after birth and continuing through 8 weeks. Nontransgenic littermate mice were analyzed in parallel to show normal heart morphology. For heart/ body weight ratio measurements, see Science Online (www.sciencemag.org).
23. M. Muthuchamy, G. P. Boivin, I. L. Grupp, D. F. Wieczorek, J. Mol. Cell. Cardiol., in press; M. Muthuchamy et al., J. Biol. Chem. 270, 30593 (1995); K. A. Palmiter, Y. Kitada, M. Muthuchamy, D. F. Wieczorek, R. J. Solaro, ibid. 271, 11611 (1996).
24. M. Muthuchamy, G. P. Boivin, I. L. Grupp, D. F. Wieczorek, J. Mol. Cell. Cardiol., in press; M. Muthuchamy et al., J. Biol. Chem. 270, 30593 (1995); K. A. Palmiter, Y. Kitada, M. Muthuchamy, D. F. Wieczorek, R. J. Solaro, ibid. 271, 11611 (1996).
25. M. Muthuchamy, G. P. Boivin, I. L. Grupp, D. F. Wieczorek, J. Mol. Cell. Cardiol., in press; M. Muthuchamy et al., J. Biol. Chem. 270, 30593 (1995); K. A. Palmiter, Y. Kitada, M. Muthuchamy, D. F. Wieczorek, R. J. Solaro, ibid. 271, 11611 (1996).
26. Overexpression of the β-tropomyosin fetal isoform in transgenic mouse hearts results in dilated cardiomyopathy by 10 days after birth. Transgenic and nontransgenic mice are phenotypically indistinguishable at 3 days after birth. The two groups were treated with CsA (15 mg/kg twice a day) beginning on day 2 after birth and continuing through day 10, at which time the untreated transgenics began to die from severe cardiac dilation.
27. M. C. Colbert et al., J. Clin. Invest. 100, 1958 (1997).
28. Transgenic mice expressing an activated RAR in the heart show phenotypic signs of hypertrophy by 8 weeks of age. CsA was administered as in (14).
29. J. Y. Le Guennec, E. White, F. Gannier, J. A. Argibay, D. Garnier, Exp. Physiol. 76, 975 (1991); K. Hongo, E. White, C. H. Orchard, Am J. Physiol. 269, C690 (1995).
30. J. Y. Le Guennec, E. White, F. Gannier, J. A. Argibay, D. Garnier, Exp. Physiol. 76, 975 (1991); K. Hongo, E. White, C. H. Orchard, Am J. Physiol. 269, C690 (1995).
31. A. Rao, C. Luo, P. G. Hogan, Annu. Rev. Immunol. 15, 707 (1997).
32. J. James and J. Robbins, Am. J. Physiol. 273, H2105 (1997).
33. L. S. Maier, R. Brandes, B. Pieske, D. M. Bers, ibid. 274, H1361 (1998).
34. Six female Sprague-Dawley rats (200 to 225 g) were used for each treatment group. CsA (20 mg/kg once a day by intraperitoneal injection) was begun 2 days before surgical banding of the abdominal aorta above the renal arteries or sham operation. Treatment was maintained for six additional days, at which time the experiment was terminated because of lethality in the banded, CsA-treated group of rats. Lethality was presumably attributable to the lack of an adequate hypertrophic response that normally compensates for reduced blood flow below the level of an aortic constriction.
35. H. O. Ventura, F. S. Malik, M. R. Mehra, D. D. Stapleton, F. W. Smart, Curr. Opin. Cardiol. 12, 375 (1997).
36. A. Haverich, A. Costard-Jackle, J. Cremer, G. Herrmann, R. Simon, Transplant Proc. 26, 2713 (1994).
37. We thank S. Witt and T. Kimball for assistance with echocardiography. Supported by American Heart Association Scientist Development Grant 9730035N (J.D.M.), NIH grant HL58224-01 (M.A.S.), and funds from the Children's Hospital Research Foundation.